Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes

被引:17
|
作者
Johnston, S. [1 ]
Janning, S. W. [2 ]
Haas, G. P. [3 ]
Wilson, K. L. [1 ]
Smith, D. M. [1 ]
Reckard, G. [3 ]
Quan, S-P [3 ]
Bukofzer, S. [3 ]
机构
[1] Thomson Reuters, Washington, DC USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
[3] Astellas Pharma Global Dev, Deerfield, IL USA
关键词
EXTENDED-RELEASE; RISK-FACTORS; PREVALENCE; INCONTINENCE; THERAPY; TERMINOLOGY; SYMPTOMS; IMPACT; WOMEN; RATES;
D O I
10.1111/j.1742-1241.2012.03009.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: This retrospective administrative claims-based study evaluated comparative persistence and adherence to overactive bladder (OAB) medications in US patients with and without diabetes. Methods: Patients = 18 years who initiated OAB medications between 1 January 2005 and 30 June 2008 were analysed from the Truven Health MarketScan (R) Commercial and Medicare Supplemental databases. A 12-month baseline period prior to OAB medication initiation was used to classify patients into diabetes and non-diabetes cohorts, and measure demographic and clinical characteristics. Patients in each cohort were directly matched 1 : 1 based on index year, age, gender and geographic region. Multiple logistic regression was used to compare cohorts on outcomes of = 80% adherence to OAB medications and refilling a second OAB medication prescription. Coxs proportional hazards model compared time to non-persistence with OAB medications between both cohorts. Results: In total, 36,560 patients were included in each cohort. Compared with the non-diabetes cohort, the diabetes cohort had 21.5% higher odds of = 80% adherence to OAB medications, 16.6% higher odds of filling a second OAB medication prescription and 10.3% lower hazard of non-persistence with OAB medications during a 12-month evaluation period. Conclusions: Patients with diabetes were more persistent and adherent to OAB medications and had higher odds of filling a second medication prescription than patients without diabetes. Further research is needed to identify factors responsible for these findings.
引用
收藏
页码:1042 / 1051
页数:10
相关论文
共 50 条
  • [21] Cognitive testing and overactive bladder medications
    Durai, R.
    Hoque, H.
    Davies, T. W.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (05) : 823 - 825
  • [22] Predictors of discontinuing overactive bladder medications
    Brubaker, Linda
    Fanning, Kristina
    Goldberg, Erica L.
    Benner, Joshua S.
    Trocio, Jeffrey N.
    Bavendam, Tamara
    Jumadilova, Zhanna
    BJU INTERNATIONAL, 2010, 105 (09) : 1283 - 1290
  • [23] Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis
    Sussman, D.
    Yehoshua, A.
    Kowalski, J.
    Lee, W.
    Kish, J.
    Chaudhari, S.
    Murray, B.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (3-4)
  • [24] Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents
    Lua, Lannah L.
    Pathak, Prathamesh
    Dandolu, Vani
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 (08) : 2123 - 2131
  • [25] Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan
    D'Souza, Anna O.
    Smith, Michael J.
    Miller, Lesley-Ann
    Doyle, Joseph
    Ariely, Rinat
    JOURNAL OF MANAGED CARE PHARMACY, 2008, 14 (03): : 291 - 301
  • [26] Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature
    Sexton, C. C.
    Notte, S. M.
    Maroulis, C.
    Dmochowski, R. R.
    Cardozo, L.
    Subramanian, D.
    Coyne, K. S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (05) : 567 - 585
  • [27] PERSISTENCE WITH ANTIMUSCARINICS IN A EUROPEAN STUDY OF PATIENTS WITH OVERACTIVE BLADDER SYNDROME
    Blok, B.
    Van Kerrebroeck, P.
    Buijs, S.
    De Vries, C.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2009, 20 : S192 - S193
  • [28] Overactive Bladder Medication Adherence When Medication is Free to Patients
    Sears, Christine L. G.
    Lewis, Christa
    Noel, Kathleen
    Albright, Todd S.
    Fischer, John R.
    JOURNAL OF UROLOGY, 2010, 183 (03): : 1077 - 1081
  • [29] Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
    Amin, Katherine
    Moskowitz, Dena
    Kobashi, Kathleen C.
    Lee, Una J.
    Lucioni, Alvaro
    JOURNAL OF UROLOGY, 2019, 201 (05): : 973 - 978
  • [30] DO PATIENTS DISCONTINUE OVERACTIVE BLADDER MEDICATIONS AFTER SACRAL NEUROMODULATION?
    Amin, Katherine
    Moskowitz, Dena
    Kobashi, Kathleen C.
    Lee, Una J.
    Lucioni, Alvaro
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1015 - E1015